Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.00

Xeris Biopharma (NASDAQ:XERS) had its price target lifted by Leerink Partners from $5.00 to $6.00 in a research note released on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also commented on the company. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.92.

Xeris Biopharma Trading Up 0.4 %

Shares of XERS stock traded up $0.02 on Friday, reaching $4.26. 793,105 shares of the company’s stock were exchanged, compared to its average volume of 1,912,517. The stock has a market capitalization of $634.34 million, a PE ratio of -9.41 and a beta of 2.32. Xeris Biopharma has a 52 week low of $1.69 and a 52 week high of $4.50. The company’s fifty day simple moving average is $3.57 and its 200 day simple moving average is $3.26.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently bought and sold shares of the company. Legato Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $482,000. Barclays PLC raised its position in shares of Xeris Biopharma by 87.8% in the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after buying an additional 151,685 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Xeris Biopharma by 2.9% in the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after buying an additional 93,091 shares in the last quarter. Principal Financial Group Inc. boosted its position in Xeris Biopharma by 30.3% during the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock worth $292,000 after acquiring an additional 23,843 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Xeris Biopharma during the 3rd quarter valued at about $44,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.